These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Effects of long-term exposure to traffic-related air pollution on respiratory and cardiovascular mortality in the Netherlands: the NLCS-AIR study. Brunekreef B; Beelen R; Hoek G; Schouten L; Bausch-Goldbohm S; Fischer P; Armstrong B; Hughes E; Jerrett M; van den Brandt P Res Rep Health Eff Inst; 2009 Mar; (139):5-71; discussion 73-89. PubMed ID: 19554969 [TBL] [Abstract][Full Text] [Related]
6. [Calibrating the SCORE cardiovascular risk chart for use in Spain]. Sans S; Fitzgerald AP; Royo D; Conroy R; Graham I Rev Esp Cardiol; 2007 May; 60(5):476-85. PubMed ID: 17535758 [TBL] [Abstract][Full Text] [Related]
7. What is my risk of developing cardiovascular disease? Graham IM; Cooney MT; Dudina A; Squarta S Eur J Cardiovasc Prev Rehabil; 2009 Aug; 16 Suppl 2():S2-7. PubMed ID: 19675432 [No Abstract] [Full Text] [Related]
8. New guidance aims to identify people at risk of early death. Hairon N Nurs Times; 2008 Oct 7-13; 104(40):21-2. PubMed ID: 18947042 [No Abstract] [Full Text] [Related]
9. A modern fairy tale. Ferrari R; Guardigli G; Tavazzi L Eur J Cardiovasc Prev Rehabil; 2009 Aug; 16 Suppl 2():S65-7. PubMed ID: 19675442 [No Abstract] [Full Text] [Related]
10. Aspirin for the primary prevention of adverse cardiovascular events. Estes K; Thomure J Crit Care Nurs Q; 2008; 31(4):324-39. PubMed ID: 18815480 [TBL] [Abstract][Full Text] [Related]
11. Polish Forum for Prevention Guidelines on the so-called new cardiovascular risk factors and markers, which have a potentially significant role in the strategy for the prevention of cardiovascular diseases. Undas A; Podolec P; Kopeć G; Pajak A; Gasior Z; Małecki M; Pasowicz M; Rynkiewicz A; Torbicki A; Zdrojeski T; Czarnecka D; Drygas W; Godycki-Cwirko M; Kozek E; Naruszewicz M; Opala G; Stańczyk J; Sieradzki J Kardiol Pol; 2007 Nov; 65(11):1396-8. PubMed ID: 18303602 [No Abstract] [Full Text] [Related]
12. Sample size calculations in the presence of competing risks. Latouche A; Porcher R Stat Med; 2007 Dec; 26(30):5370-80. PubMed ID: 17955563 [TBL] [Abstract][Full Text] [Related]
13. Value and limitations of existing scores for the assessment of cardiovascular risk: a review for clinicians. Cooney MT; Dudina AL; Graham IM J Am Coll Cardiol; 2009 Sep; 54(14):1209-27. PubMed ID: 19778661 [TBL] [Abstract][Full Text] [Related]
14. [The role of adiposity and inactivity in primary prevention of cardiovascular disease]. König D; Bönner G; Berg A Herz; 2007 Oct; 32(7):553-9. PubMed ID: 17972028 [TBL] [Abstract][Full Text] [Related]
15. Rosuvastatin outcomes study JUPITER closes early due to evidence of benefit. Cardiovasc J Afr; 2008; 19(2):117. PubMed ID: 18516361 [No Abstract] [Full Text] [Related]